AAV Innovation Summit 2024

Advancing Gene Therapy Through Collective Innovation

Mark Swendsen, Chief Revenue Officer at Form Bio kicks off the inaugural AAV Innovation Summit by introducing the speakers, the AAV working group, and  the key industry challenges, and how the community is advancing with robust digital infrastructure.

Understanding AAV Vector Genome Integrity

Phillip Tai, PhD, Assistant Professor, Horae Gene Therapy Center, UMass Chan Medical School, explores the development and application of advanced sequencing methodologies to address the challenges of heterogeneity in AAV vector design.

Designing rAAV Vectors Using In Silico Vector Modeling

Adam Cockrell, PhD, Sr. Director Vector Biology at Solid Biosciences delves into the characterization and design of AAV vectors, focusing on the use of in silico technologies and vector modeling to expedite early research and improve therapeutic development.

CDMO Perspective: AAV Manufacturing Challenges & the Role of AI

Nithya Jesuraj, PhD, Director, Commercial R&D at National Resilience explores the challenges in AAV manufacturing and the role of AI in addressing them.

AI & In Silico Tools for Faster, More Predictable AAV Development

Amicia Elliott, PhD, Product Director - Life Sciences at Form Bio explores the transformative potential of AI and in silico computational tools in accelerating and enhancing the predictability of AAV-based gene therapy development.

Standardized Nomenclature & Reporting for Long-Read Sequencing & Analysis in rAAV Vectors

In this panel discussion, members of the AAV Working Group delve into the current challenges in gene therapy, the use of long-read sequencing for genome integrity and vector design, FDA's requirements for genome integrity measurements in IND applications, and more.

State of the Gene Therapy Industry

Tim Hunt, CEO at Alliance for Regenerative Medicine discusses the industrialization of the cell and gene therapy field, highlighting the role of AI and digital innovation in advancing the sector.